메뉴 건너뛰기




Volumn 4, Issue 1, 2015, Pages 83-93

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl

Author keywords

Diabetes; Docosahexaenoic acid; Dyslipidemia; Eicosapentaenoic acid; Icosapent ethyl; Lovaza; Low density lipoprotein cholesterol; Triglycerides; Vascepa

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; TRIACYLGLYCEROL;

EID: 84942614260     PISSN: 21938261     EISSN: 21936544     Source Type: Journal    
DOI: 10.1007/s40119-014-0032-9     Document Type: Article
Times cited : (21)

References (36)
  • 1
    • 84892649479 scopus 로고    scopus 로고
    • Standards of medical care in diabetes–2014
    • American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37 Suppl 1:S14–80.
    • (2014) Diabetes Care , vol.37 , pp. S14-S80
  • 2
    • 84860144206 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis
    • Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1–78.
    • (2012) Endocr Pract , vol.18
    • Jellinger, P.S.1    Smith, D.A.2    Mehta, A.E.3    Ganda, O.4    Handelsman, Y.5    Rodbard, H.W.6
  • 3
    • 84859049036 scopus 로고    scopus 로고
    • The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis
    • PID: 22463676
    • Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12:2.
    • (2012) BMC Endocr Disord , vol.12 , pp. 2
    • Murad, M.H.1    Hazem, A.2    Coto-Yglesias, F.3    Dzyubak, S.4    Gupta, S.5    Bancos, I.6
  • 4
    • 84924334268 scopus 로고    scopus 로고
    • Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
    • PID: 25301574
    • Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G. Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol. 2014;13:135.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 135
    • Miselli, M.A.1    Nora, E.D.2    Passaro, A.3    Tomasi, F.4    Zuliani, G.5
  • 5
    • 85027956925 scopus 로고    scopus 로고
    • Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association
    • PID: 21502576
    • Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.
    • (2011) Circulation , vol.123 , pp. 2292-2333
    • Miller, M.1    Stone, N.J.2    Ballantyne, C.3    Bittner, V.4    Criqui, M.H.5    Ginsberg, H.N.6
  • 7
    • 80051670126 scopus 로고    scopus 로고
    • Fish oils in the treatment of dyslipidemia and cardiovascular disease
    • Kwiterovich PO, (ed), Lippincott Williams & Wolters Kluwer, Philadelphia
    • Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. Philadelphia: Lippincott Williams & Wolters Kluwer; 2010. p. 245–57.
    • (2010) The Johns Hopkins textbook of dyslipidemia , pp. 245-257
    • Bays, H.1
  • 8
    • 79961054708 scopus 로고    scopus 로고
    • Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events
    • COI: 1:CAS:528:DC%2BC3MXhs1eju7zE, PID: 22051327
    • Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 2047-2067
    • Mozaffarian, D.1    Wu, J.H.2
  • 9
    • 85118092730 scopus 로고    scopus 로고
    • Lovaza [package insert]. Research Triangle Park: GlaxoSmithKline; 2014
    • Lovaza [package insert]. Research Triangle Park: GlaxoSmithKline; 2014.
  • 10
    • 85118090691 scopus 로고    scopus 로고
    • Vascepa [package insert]. Bedminster: Amarin Pharma Inc.; 2013
    • Vascepa [package insert]. Bedminster: Amarin Pharma Inc.; 2013.
  • 11
    • 81155139591 scopus 로고    scopus 로고
    • Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis
    • COI: 1:CAS:528:DC%2BC3MXhsVaht7vN, PID: 21975919
    • Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–83.
    • (2011) Curr Atheroscler Rep , vol.13 , pp. 474-483
    • Wei, M.Y.1    Jacobson, T.A.2
  • 13
    • 80051784104 scopus 로고    scopus 로고
    • Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) trial]
    • COI: 1:CAS:528:DC%2BC3MXhtVajtrbF, PID: 21683321
    • Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) trial]. Am J Cardiol. 2011;108:682–90.
    • (2011) Am J Cardiol , vol.108 , pp. 682-690
    • Bays, H.E.1    Ballantyne, C.M.2    Kastelein, J.J.3    Isaacsohn, J.L.4    Braeckman, R.A.5    Soni, P.N.6
  • 14
    • 84866124338 scopus 로고    scopus 로고
    • Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
    • COI: 1:CAS:528:DC%2BC38XhtVyktL7E, PID: 22819432
    • Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.
    • (2012) Am J Cardiol , vol.110 , pp. 984-992
    • Ballantyne, C.M.1    Bays, H.E.2    Kastelein, J.J.3    Stein, E.4    Isaacsohn, J.L.5    Braeckman, R.A.6
  • 15
    • 0037126526 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 16
    • 84908397421 scopus 로고    scopus 로고
    • National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary
    • PID: 25234560
    • Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8:473–88.
    • (2014) J Clin Lipidol , vol.8 , pp. 473-488
    • Jacobson, T.A.1    Ito, M.K.2    Maki, K.C.3    Orringer, C.E.4    Bays, H.E.5    Jones, P.H.6
  • 17
    • 84893560587 scopus 로고    scopus 로고
    • Potential benefits of icosapent ethyl on the lipid profile: case studies
    • COI: 1:CAS:528:DC%2BC2cXhtlWhu7bM, PID: 24516343
    • Hilleman DE, Malesker MA. Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol. 2014;8:13–5.
    • (2014) Clin Med Insights Cardiol , vol.8 , pp. 13-15
    • Hilleman, D.E.1    Malesker, M.A.2
  • 18
    • 84906924767 scopus 로고    scopus 로고
    • A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients
    • PID: 24977343
    • Castaldo RS. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. Postgrad Med. 2014;126:268–73.
    • (2014) Postgrad Med , vol.126 , pp. 268-273
    • Castaldo, R.S.1
  • 19
    • 84866146620 scopus 로고    scopus 로고
    • Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline
    • COI: 1:CAS:528:DC%2BC38XhtlymurbF, PID: 22962670
    • Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 2969-2989
    • Berglund, L.1    Brunzell, J.D.2    Goldberg, A.C.3    Goldberg, I.J.4    Sacks, F.5    Murad, M.H.6
  • 20
    • 0015348189 scopus 로고
    • Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
    • COI: 1:CAS:528:DyaE38Xkslagsbw%3D, PID: 4337382
    • Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    • (1972) Clin Chem , vol.18 , pp. 499-502
    • Friedewald, W.T.1    Levy, R.I.2    Fredrickson, D.S.3
  • 21
    • 84880019277 scopus 로고    scopus 로고
    • Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
    • COI: 1:CAS:528:DC%2BC3sXht1ejtb%2FN, PID: 23835245
    • Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.
    • (2013) Cardiovasc Diabetol , vol.12 , pp. 100
    • Brinton, E.A.1    Ballantyne, C.M.2    Bays, H.E.3    Kastelein, J.J.4    Braeckman, R.A.5    Soni, P.N.6
  • 22
    • 33749154105 scopus 로고    scopus 로고
    • Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
    • COI: 1:CAS:528:DC%2BD28XhtVajsr3L, PID: 16530201
    • Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189:19–30.
    • (2006) Atherosclerosis , vol.189 , pp. 19-30
    • Balk, E.M.1    Lichtenstein, A.H.2    Chung, M.3    Kupelnick, B.4    Chew, P.5    Lau, J.6
  • 23
    • 0345109256 scopus 로고    scopus 로고
    • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico
    • GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.
    • (1999) Lancet , vol.354 , pp. 447-455
  • 24
    • 53049110571 scopus 로고    scopus 로고
    • Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
    • GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.
    • (2008) Lancet , vol.372 , pp. 1223-1230
    • Investigators, G.I.S.S.I.-H.F.1
  • 25
    • 78549233384 scopus 로고    scopus 로고
    • n-3 fatty acids and cardiovascular events after myocardial infarction
    • COI: 1:CAS:528:DC%2BC3cXhsVykt7jI, PID: 20929341
    • Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.
    • (2010) N Engl J Med , vol.363 , pp. 2015-2026
    • Kromhout, D.1    Giltay, E.J.2    Geleijnse, J.M.3
  • 26
    • 84864219466 scopus 로고    scopus 로고
    • n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
    • ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–18.
    • (2012) N Engl J Med , vol.367 , pp. 309-318
  • 27
    • 78650169331 scopus 로고    scopus 로고
    • OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction
    • COI: 1:CAS:528:DC%2BC3cXhsV2gu73K, PID: 21060071
    • Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–9.
    • (2010) Circulation , vol.122 , pp. 2152-2159
    • Rauch, B.1    Schiele, R.2    Schneider, S.3    Diller, F.4    Victor, N.5    Gohlke, H.6
  • 28
    • 33947583493 scopus 로고    scopus 로고
    • Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
    • COI: 1:CAS:528:DC%2BD2sXjs1Ohtro%3D, PID: 17398308
    • Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.
    • (2007) Lancet , vol.369 , pp. 1090-1098
    • Yokoyama, M.1    Origasa, H.2    Matsuzaki, M.3    Matsuzawa, Y.4    Saito, Y.5    Ishikawa, Y.6
  • 29
    • 49749128376 scopus 로고    scopus 로고
    • Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
    • COI: 1:CAS:528:DC%2BD1cXhtVensb7J, PID: 18667204
    • Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135–40.
    • (2008) Atherosclerosis , vol.200 , pp. 135-140
    • Saito, Y.1    Yokoyama, M.2    Origasa, H.3    Matsuzaki, M.4    Matsuzawa, Y.5    Ishikawa, Y.6
  • 30
    • 84869170925 scopus 로고    scopus 로고
    • Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial
    • COI: 1:CAS:528:DC%2BC38XhvVCmtrjM, PID: 23128104
    • Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA. 2012;308:2001–11.
    • (2012) JAMA , vol.308 , pp. 2001-2011
    • Mozaffarian, D.1    Marchioli, R.2    Macchia, A.3    Silletta, M.G.4    Ferrazzi, P.5    Gardner, T.J.6
  • 31
    • 84875802805 scopus 로고    scopus 로고
    • Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis
    • COI: 1:CAS:528:DC%2BC3sXmtVClsQ%3D%3D, PID: 23179632
    • Larsson SC, Orsini N, Wolk A. Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. Eur J Epidemiol. 2012;27:895–901.
    • (2012) Eur J Epidemiol , vol.27 , pp. 895-901
    • Larsson, S.C.1    Orsini, N.2    Wolk, A.3
  • 32
    • 84877624255 scopus 로고    scopus 로고
    • The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–8.
    • (2013) N Engl J Med , vol.368 , pp. 1800-1808
  • 33
    • 68149166448 scopus 로고    scopus 로고
    • Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease
    • COI: 1:CAS:528:DC%2BD1MXptVejsLw%3D, PID: 19423946
    • Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73:1283–90.
    • (2009) Circ J , vol.73 , pp. 1283-1290
    • Matsuzaki, M.1    Yokoyama, M.2    Saito, Y.3    Origasa, H.4    Ishikawa, Y.5    Oikawa, S.6
  • 34
    • 84903727023 scopus 로고    scopus 로고
    • Loss-of-function mutations in APOC3, triglycerides, and coronary disease
    • TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
    • (2014) N Engl J Med , vol.371 , pp. 22-31
  • 36
    • 85118091377 scopus 로고    scopus 로고
    • A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Accessed Nov 26, 2014
    • A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). http://clinicaltrials.gov/show/NCT01492361. Accessed Nov 26, 2014.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.